Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 186.6% in March

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 6,607 shares, an increase of 186.6% from the March 15th total of 2,305 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 11,231 shares, the days-to-cover ratio is currently 0.6 days.

Global X Genomics & Biotechnology ETF Stock Down 1.6%

Shares of Global X Genomics & Biotechnology ETF stock traded down $0.73 on Friday, hitting $43.90. 3,503 shares of the company’s stock traded hands, compared to its average volume of 9,385. The stock has a market cap of $49.17 million, a P/E ratio of -18.76 and a beta of 1.23. The firm’s 50-day moving average is $45.14 and its 200 day moving average is $44.95. Global X Genomics & Biotechnology ETF has a 52-week low of $28.88 and a 52-week high of $51.42.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its stake in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares during the last quarter. Sei Investments Co. boosted its position in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after buying an additional 12,105 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Global X Genomics & Biotechnology ETF by 30.9% during the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after buying an additional 4,615 shares during the period. Creative Financial Designs Inc. ADV boosted its position in shares of Global X Genomics & Biotechnology ETF by 4.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock worth $551,000 after buying an additional 481 shares during the period. Finally, U.S. Capital Wealth Advisors LLC acquired a new position in shares of Global X Genomics & Biotechnology ETF during the fourth quarter worth approximately $575,000. 56.95% of the stock is currently owned by institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.